VERVE THERAPEUTICS INC's ticker is VERV and the CUSIP is 92539P101. A total of 137 filers reported holding VERVE THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.34 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,813,963 | -23.5% | 363,044 | +8.2% | 0.00% | -50.0% |
| Q2 2023 | $6,289,481 | +35.3% | 335,439 | +4.1% | 0.00% | +100.0% |
| Q1 2023 | $4,647,566 | -25.1% | 322,300 | +0.5% | 0.00% | -50.0% |
| Q4 2022 | $6,203,165 | -41.2% | 320,577 | +4.5% | 0.00% | -50.0% |
| Q3 2022 | $10,541,000 | +376.1% | 306,853 | +111.8% | 0.00% | +300.0% |
| Q2 2022 | $2,214,000 | -36.8% | 144,890 | -5.6% | 0.00% | 0.0% |
| Q1 2022 | $3,505,000 | -9.2% | 153,550 | +46.6% | 0.00% | 0.0% |
| Q4 2021 | $3,862,000 | -20.1% | 104,726 | +1.9% | 0.00% | -50.0% |
| Q3 2021 | $4,833,000 | – | 102,810 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Alphabet Inc. | 10,974,011 | $167,683,000 | 9.10% |
| ARCH Venture Management, LLC | 2,508,809 | $38,335,000 | 4.67% |
| Casdin Capital, LLC | 3,138,167 | $47,951,000 | 4.05% |
| M28 Capital Management LP | 178,500 | $2,727,000 | 3.06% |
| Redmile Group, LLC | 1,833,547 | $28,017,000 | 1.07% |
| Cormorant Asset Management, LP | 700,710 | $10,707,000 | 0.81% |
| Novo Holdings A/S | 927,100 | $14,166,000 | 0.70% |
| Pinz Capital Management, LP | 51,800 | $792,000 | 0.54% |
| PFM Health Sciences, LP | 845,186 | $12,914,000 | 0.49% |
| Artal Group S.A. | 400,000 | $6,112,000 | 0.33% |